Related Experiment Video
Updated: May 29, 2026
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Characterization of novel synthesized small molecular compounds against non-small cell lung cancer
Yunge Zhao1, Mark Turlington, Damien J LaPar
1Division of Thoracic and Cardiovascular Surgery, Department of Surgery, University of Virginia, Charlottesville, Virginia 22908-0679, USA.
Background:
With the exception of surgery, the standard platinum-based chemotherapeutic agents are the preferred treatment for non-small cell lung cancer (NSCLC); however little improvement (5-year survival) has been made. Therefore it is highly desirable to develop innovative therapeutic agents for NSCLC treatment.
Methods:
Highly enantioselective synthetic methods were developed and a broad compound library was established. Cell toxicity, cell sensitivity, cell proliferation, cell invasion, and three-dimensional colony formation assays were used to assess the anticancer potential of these compounds in non-small-cell lung cancer (NSCLC) cell lines.
Results:
We found that the S-form of compound PL54 (PL54S, 5-20 microM) exhibited strong anticancer activity in 5 tested NSCLC cell lines. We further synthesized a highly pure R-form enantiomer of PL54 (PL54R) and its racemate (PL54Rac) and characterized their anticancer activities. The results showed that PL54S is more potent than PL54R and PL54Rac against the tested cell lines. Furthermore, less cellular toxicity was observed in the normal human lung fibroblasts. Similarly, PL54S displayed greater anti-colony formation activity compared with PL54R and PL54Rac. The cellular sensitivity assay revealed that PL54S and PL54Rac significantly suppressed cologenic formation compared with PL54R and dimethyl sulfoxide controls (p<0.01). All PL54 compounds (5 to 20 microM) significantly inhibited cell proliferation and invasion of the A549 cell line (p<0.01). A soft agar colony formation assay revealed that PL54S and PL54Rac (10 mM), but not PL54R, significantly inhibited colony formation of tested NSCLC cells (p<0.01).
Conclusions:
The stereospecific compounds may prove to be a novel technique for the treatment of NSCLC.
Insights
The S-form of compound PL54 demonstrates potent anticancer activity against non-small cell lung cancer (NSCLC) cell lines, offering a promising new therapeutic avenue. This stereospecific compound shows greater efficacy and less toxicity than its R-form or racemic mixture.
Area of Science:
- Medicinal Chemistry
- Oncology
- Pharmacology
Background:
- Standard platinum-based chemotherapy for non-small cell lung cancer (NSCLC) has shown limited improvement in 5-year survival rates.
- There is a critical need for innovative therapeutic agents to enhance NSCLC treatment outcomes.
Purpose of the Study:
- To develop and evaluate novel stereospecific compounds for their anticancer potential in non-small cell lung cancer (NSCLC).
- To assess the efficacy and safety of different enantiomers of compound PL54 against NSCLC cell lines.
Main Methods:
- Enantioselective synthesis was employed to create a library of compounds.
- In vitro assays evaluated cell toxicity, sensitivity, proliferation, invasion, and colony formation in NSCLC cell lines.
Main Results:
- The S-enantiomer of PL54 (PL54S) exhibited significant anticancer activity against five NSCLC cell lines at concentrations of 5-20 microM.
- PL54S demonstrated superior potency compared to its R-enantiomer (PL54R) and racemic mixture (PL54Rac), with reduced toxicity in normal lung fibroblasts.
- PL54S and PL54Rac significantly inhibited cell proliferation, invasion, and colony formation in NSCLC cells, with PL54R showing less activity.
Conclusions:
- Stereospecific compounds, such as PL54S, represent a novel and potentially effective strategy for treating non-small cell lung cancer (NSCLC).
- The differential activity of enantiomers highlights the importance of stereochemistry in developing targeted NSCLC therapies.
